COVID-19: AIIMS panel nod to human clinical trial of Covaxin

DY365
DY365
Published: July 18,2020 11:32 PM
DY365

Story highlights

July 18, 2020: On Saturday , the AIIMS Ethics Committee gave its nod for a human clinical trial of the indigenously developed COVID-19 vaccine, Covaxin.

July 18, 2020: The AIIMS Ethics Committee on Saturday gave its nod for a human clinical trial of the indigenously developed COVID-19 vaccine, Covaxin. Following this, the premier hospital is likely to begin the exercise by enrolling healthy volunteers from Monday.



AIIMS-Delhi is among the 12 sites selected by the ICMR for conducting phase I and II of the human trials. In phase I, the vaccine would be tested on 375 volunteers, at most 100 of whom would be from AIIMS.



The Health Ministry on Saturday said the total number of recoveries of India’s coronavirus patients has exceeded the active cases by 2.95 lakh. The country’s actual COVID-19 caseload is 3,58,692, while close to 18,000 people have recuperated from the disease in 24 hours taking the the number of recoveries to 6,53,750.



Globally, over 14 million people (14,106,753) have been infected with the virus and 602,656 have died. It has taken just four days to climb to 14 million cases from 13 million recorded on July 13. The United States, with more than 3.6 million confirmed cases, is still seeing huge daily jumps in its first wave of COVID-19 infections.